Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. - Wikidata - wikimedia - TriplyDB

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

http://www.wikidata.org/entity/Q36060239

about

CAR models: next-generation CAR modifications for enhanced T-cell function CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances Novel immunotherapies in lymphoid malignancies CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect CARs in chronic lymphocytic leukemia -- ready to drive Progress and prospects for engineered T cell therapies Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment Genetically modified T cells for the treatment of malignant disease Chimeric antigen receptor therapy for cancer Current translational and clinical practices in hematopoietic cell and gene therapy Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Toxicity and management in CAR T-cell therapy CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date Smart CARs engineered for cancer immunotherapy Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD Chimeric antigen receptor-modified T cells for acute lymphoid leukemia CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia Engineered T cells for cancer treatment Immunotherapy in hematologic malignancies: past, present, and future.Strategies to genetically engineer T cells for cancer immunotherapy.Genome-Edited T Cell Therapies.Biology and clinical application of CAR T cells for B cell malignancies The basic principles of chimeric antigen receptor design.CAR-modified T-cell therapy for cancer: an updated review.Driving CAR T-cells forward Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

P2860

Q26745600-D401CCA0-E0F7-46BD-9E59-3F0D37D57B57 Q26749139-2D8D6124-5B8F-4A8B-B2CA-545230BF6FF6 Q26771159-F8BAC8CF-BD26-42C3-90BF-4D8E71B37945 Q26773135-11714FEE-3C29-4EA1-BA75-767381C8D705 Q26773309-6D33943C-4491-463C-9B76-BB2999CF60EE Q26775720-FCE00387-1702-475F-B01E-F0656CC2A677 Q26777394-D1B6B9E9-AEA2-4F1F-A0B9-E4D3FBB96EA1 Q26783433-A9F496A3-2B39-40D2-8FC1-766A81333720 Q26795540-7CD2FA79-92A6-45AA-9132-5C33A06964F4 Q26826830-CDEED237-B81B-405C-8711-3F269146DAF0 Q26830526-D2C9CA84-5374-4A0D-85A6-CC6A9139F3CB Q26852923-3965FE5A-ECB7-42E5-ADA6-E964A926651C Q26852927-CF8B9BE1-B900-479A-9AFE-B822B396B964 Q26860657-73DD4CB0-2EE3-465F-878A-5100607520BE Q27013599-67FB2878-AA91-4CE7-A5C4-D021226D4288 Q27024456-8F5C6530-437C-465C-91C0-7D14BBFBB0BB Q27304386-0B38A727-1363-4BEF-8AD3-CC10B4EFD35B Q28075314-AC0F587A-AC3B-459C-9334-92631FCEC4A7 Q28081600-A32BBA23-2225-4F07-9B22-621D33DB0B66 Q28083296-042C2250-40D8-49E5-91F5-8323490CC9A2 Q28087236-B0C14522-1B32-4861-BC58-ED9911691ABA Q28389778-0C871F72-06F4-478A-A5A7-BCA6ADF43881 Q29620130-4A1CECDB-C70F-4CF9-9F00-89425FE1EB61 Q29620607-F1AEA73B-5F8B-46FE-BB50-DA87E8CC2A9C Q29620717-B1DCC229-4B2A-4C5B-B742-81C4AFED601C Q29622949-DF2EE61D-D9B5-4D1A-8DB0-51FBB4F615AD Q33564364-02B2AE8E-D407-4DC3-A2CA-0380288A21C4 Q33578792-D4AE7EDE-0A70-4B57-82F5-E8023AE755BF Q33593865-CB5436EF-8E71-4EFE-BFDD-EA8405BE736B Q33655849-38DEFD53-9214-4BF6-ABC0-4D1B5304F163 Q33729598-9A6E8699-0D85-47F0-A8D5-BB5200D02900 Q33907565-CCC13596-0282-4B86-B4FC-15C2A6749D5D Q34036213-C413284A-9330-4922-BA6B-06D7CB879F67 Q34044213-4F2A3CFA-6702-406A-988D-557C2E53E45D Q34046505-5641B252-2DEC-4086-BFEF-974891F19FEB Q34122292-AABB7963-4E3D-4282-B5EA-8AC98DDF8625 Q34248531-9D9123F1-FC06-4CE3-869D-E4A5DE4E7A65 Q34270375-C2E0863B-C974-4015-B72B-F1562188CF1E Q34309388-8A4DC7AC-F65D-4039-86B3-2CBA3C8D2539 Q34360292-6EE2A1B7-6D9C-4CDC-B062-BCF33172923D

P2860

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

http://www.wikidata.org/entity/Q36060239

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Antitransgene rejection respon ...... redirected T cells in humans.

@ast

Antitransgene rejection respon ...... redirected T cells in humans.

@en

type

label

Antitransgene rejection respon ...... redirected T cells in humans.

@ast

Antitransgene rejection respon ...... redirected T cells in humans.

@en

prefLabel

Antitransgene rejection respon ...... redirected T cells in humans.

@ast

Antitransgene rejection respon ...... redirected T cells in humans.

@en

P1433

Q36060239-165DC9F0-C04C-4627-BEBC-EB2040B06B52

P1476

Q36060239-0462DA85-5983-4CCD-AD3D-33AF238EA989

P2093

Q36060239-223D38E5-7483-4E9C-8075-35DCAD12D07A

Q36060239-33304445-AA54-43E9-B938-941E0B033BF8

Q36060239-66FEA3C9-62BF-4F4B-AB81-91626864B0BA

Q36060239-7769B263-35CD-4415-978B-BB2488443482

Q36060239-906ADD7B-4CBA-496B-9051-AF209CF1F129

Q36060239-D746FF1C-986A-497B-BA90-D63344019D99

Q36060239-F08B969D-E8A0-415E-BF98-0E91080F4ECE

P2860

Q36060239-10F17FCF-2164-42AE-B395-988F2F58F470

Q36060239-17AF0538-AF51-4F67-8CBA-FD0E8D56DFE0

Q36060239-19B3761E-94A7-4050-9A5A-98219918F4C5

Q36060239-2F14A7F7-0CD5-42EC-B650-FAA64FE2494A

Q36060239-2FC2393A-2D56-4062-AFB4-3106F587C49C

Q36060239-311F9EDE-AC6F-4C2C-8B55-41F5C5C88136

Q36060239-325C35C0-D46B-459D-94ED-5ED6EF52FDC1

Q36060239-4B9F3661-B05E-41D9-9FED-513E39488E60

Q36060239-54CB214B-9A18-4134-8318-94D75AFAB1E4

Q36060239-54E663A5-8C5F-411E-A179-005171A6B71D

P304

Q36060239-3F9297DE-3A06-4315-960D-A181A1211C14

P31

Q36060239-631BBA4D-798B-4984-AC66-E199942D3CC0

P356

Q36060239-77E0C832-DDF4-43A3-B5FE-7A053E7BC693

P433

Q36060239-8413C3F9-DDFC-4DCB-8180-7F578E05A6E7

P478

Q36060239-6A24B593-6AEF-49CB-8F98-D22B53A5184F

P577

Q36060239-74EB9274-CEA6-43E1-A58C-393D63CD0945

P5875

Q36060239-8346F338-4FC4-41B8-BE7E-535308A4D616

P698

Q36060239-01767010-CB88-4DB9-8B6E-CBE347BAC226

P932

Q36060239-3C068C09-8911-439C-A8DB-64DC3344AD86

P356

J.BBMT.2010.03.014

P1433

Biology of Blood and Marrow Transplantation

P1476

Antitransgene rejection respon ...... redirected T cells in humans.

@en

P2093

David DiGiusto

http://www.w3.org/2001/XMLSchema#string

Julie R Ostberg

http://www.w3.org/2001/XMLSchema#string

Laurence J Cooper

http://www.w3.org/2001/XMLSchema#string

Leslie Popplewell

http://www.w3.org/2001/XMLSchema#string

Michael C Jensen

http://www.w3.org/2001/XMLSchema#string

Michael Kalos

http://www.w3.org/2001/XMLSchema#string

Stephen J Forman

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive immunotherapy for cancer: building on success

Lineage relationship and protective immunity of memory CD8 T cell subsets

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Arrested differentiation, the self-renewing memory lymphocyte, and vaccination.

The promise and potential pitfalls of chimeric antigen receptors.

Immunotherapy for lymphomas.

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas.

P304

1245-1256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2010.03.014

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42371047

http://www.w3.org/2001/XMLSchema#string

P698

20304086

http://www.w3.org/2001/XMLSchema#string

P932

3383803

http://www.w3.org/2001/XMLSchema#string